New faces at the Bionomics
Thursday, 27 May, 2004
Adelaide drug-discovery company Bionomics (ASX:BNO, US OTC:BMICY) has appointed Dr Tim Harris, CEO and co-founder of US biotech Structural GenomiX, to its advisory board.
Harris was director of biotechnology at Glaxo Group Research in the UK, from 1989-93, and senior vice-president of R&D for Sequana Therapeutics from 1993-99. Sequana became Axys Pharmaceuticals in 1998.
The company also announced the retirement of three of its current scientific advisory board members: Prof Mathew Vadas, Prof Erkki Ruoslahti, and Prof Axel Ulrich, whose four-year terms have expired.
CEO Dr Deborah Rathjen paid tribute to Vadas, who was Bionomics' scientific co-founder, for guiding the company's formation, and for recognising the potential of genomics to improve human health.
The company has also announced the appointment of expatriate Australian -- and Adelaidean -- Dr Kerstin Holata, as its director of drug discovery.
A Flinders University graduate and PhD, Holata did postgraduate research at Northwestern University in the US, and has been working for Pfizer, validating novel ion-channel drug targets and establishing high-throughput screening systems for drug discovery.
Bionomics has a major drug-discovery program targeting central nervous system ion channel disorders including epilepsy and anxiety.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
